Healthcare model of the future

Janssen works on and markets products with a high added value for patients. In the last four years we have had as many as eleven new drugs approved.
But there is not just this focus. As part of the evolution in health care, we are also looking for new ways to make diagnoses, administer medication, identify or prevent diseases, and monitor patients.
Tomorrow all of this will be revolutionarily different from today.
Gezondheidszorgmodel van de toekomst

Private and public healthcare organizations in the EU and the US are all faced with the challenge of keeping their budgets under control, while healthcare expenditures are rising sharply. For that reason they are far more critical when negotiating pricing and reimbursement conditions with biotechnological and pharmaceutical companies. Furthermore, branded drugs are largely replaced by generic forms once the patents have expired.
"Solution-based therapy is a combination of medication-based therapy, equipment or software-based diagnostics, and components/partners from the healthcare services."
In addition, doctors in their prescription behaviour need to take more account of the rules issued by the government, public and private insurance institutions, and the wishes of patients, who have taken up a more active role in their treatment process.
It has therefore become more difficult for Life Sciences companies to recover the costs of the heavy long-term investments in the development and marketing of new products in a sound manner from a business economics point of view. In order to maintain its investment budgets, the pharmaceutical industry is therefore focusing more on those therapeutic areas where the chances of finding a therapeutic solution are more uncertain, but which also generate a higher added value for patients, healthcare organizations, and the company.
The development of offering overall healthcare solutions to our patients should be seen against this background. This means that the development of curative medicines will be just one part of the solution in the treatment of a disease. Far more emphasis will be placed on the early detection of the development of a disease and on the prevention of its progression. This means that far more partners will be involved than today to arrive at those therapeutic solutions (ICT, mobile communication, technology, domotics, etc). Openness to each other and willingness to jointly engage in sustainable innovation are basic conditions to develop such solutions successfully.